Neurodegenerative Disease Research

Do you know this story, and why it might also hold the key to curing Parkinson’s? In World War II, engineers studied returning planes riddled with bullet holes. At first, they thought reinforcing the damaged areas would save more aircraft. But statistician Abraham Wald realized the opposite - the planes that made it back told us only about tolerated injuries. The missing data were the planes that didn’t return. Protection needed to go where the bullets weren’t. Post-mortem brain omics in Parkinson’s disease carry a similar trap. They reflect the neurons resilient enough to survive, not the ones already lost. If we only study the “bullet holes” left in the surviving cells, we miss the real vulnerabilities. That’s why context matters. To build the right hypotheses, we need orthogonal perspectives: genetics, living peripheral tissues, and longitudinal multi-omic samples during disease progression - data we increasingly have thanks to The Michael J. Fox Foundation for Parkinson's Research When we brought these perspectives together, one theme was unmistakable: deficient mitophagy. Faulty recycling of damaged mitochondria as the central problem in PD. At Vincere Biosciences we've engineered molecules to restore this process and we're preparing for human clinical trials. I can't wait to see these data-driven predictions translated into relief for millions of patients!

Researchers have finally uncovered how a mysterious protein called PINK1 contributes to Parkinson’s disease—bringing fresh hope for new treatments. For years, scientists have known that PINK1 is linked to Parkinson’s, especially early-onset cases in people under 50, but until now, they had never seen what this protein looks like or how exactly it causes damage inside cells. That’s just changed, thanks to a team from Australia’s Walter and Eliza Hall Institute, who’ve revealed the protein’s full structure and how it attaches to mitochondria—the energy-making parts of our cells. PINK1 is supposed to help remove damaged mitochondria through a cleanup process called mitophagy. But in people with a PINK1 mutation, this system breaks down. Toxins build up, cells get overloaded, and brain cells—especially the energy-hungry ones that make dopamine—start dying. Since the brain replaces lost cells very slowly, this damage becomes permanent, leading to symptoms like tremors, stiffness, memory problems, and more. Using high-resolution imaging, scientists observed PINK1 in action for the first time. They saw how it senses mitochondrial damage, docks onto the affected area, and works with another protein, Parkin, to recycle it. They also pinpointed how disease-related mutations disrupt this process. Now that the protein’s structure is finally visible, drug designers can begin working on ways to “switch off” or correct the malfunction—potentially slowing or even halting Parkinson’s progression.    PMID: 33998543  PMCID: PMC9004622

A collaborative #study has uncovered a key protective mechanism that cells use to safeguard #mitochondrial #DNA (#mtDNA). Damage to mtDNA is linked to a range of debilitating conditions, including Parkinson’s, Alzheimer’s, #ALS, #cardiovascular disease, type 2 #diabetes, and accelerated aging. However, cells have built-in systems to detect and respond to such damage—and researchers have now identified one of these systems in action. Published in *Science Advances*, the study reveals that when mtDNA becomes damaged, cells activate a specialized recycling pathway involving the *retromer* protein complex and lysosomes—organelles that digest and remove waste. This process effectively eliminates faulty mitochondrial DNA, preventing its accumulation and preserving mitochondrial #health. The team found that the retromer complex, particularly the #protein *VPS35*, plays a central role. When #VPS35 activity was enhanced in #fruit flies (Drosophila), mitochondrial function improved and damaged mtDNA was cleared more efficiently. These findings, confirmed in both #human #cells and flies, suggest a highly conserved #biological response that may be harnessed to combat mitochondrial and age-related #diseases. According to lead researcher Prof. Pla-Martín and Dr. Parisa Kakanj, this discovery not only sheds light on how mitochondrial damage contributes to neurological and metabolic disorders but also points toward future #therapeutic #strategies. By enhancing the #cell’s #natural recycling systems, #scientists hope to mitigate disease progression and promote #healthier aging. RESEARCH PAPER 📄 P. Kakanj et al., "Retromer promotes the lysosomal turnover of mtDNA." Science Advances (2025) #health #healthcare #education #medicine

For decades, neuroscience treated memory as a synaptic phenomenon. Strengthen the synapse, store the memory. Long-term potentiation. Receptor density. Dendritic spine morphology. Mitochondria? Background actors. ATP factories humming in the cellular basement. Important for keeping the lights on. Not for the cognitive main event. This framing is incomplete. A 2025 study using 3D MINFLUX nanoscopy revealed something unexpected. Following fear conditioning in mice, ATP synthase physically redistributes within mitochondria located in dendritic spines of memory engram cells. Not just more ATP production. Polarized redistribution toward the postsynaptic zone. This is not housekeeping. This is architectural reorganization in response to learning. Here is what this explains. The spacing effect. Hermann Ebbinghaus documented it in 1885. Distributed practice produces more durable memories than massed practice. We have known this for 140 years. We did not know why. Now we do. Spaced training triggers long-term memory formation by extending mitochondrial metabolic activity for several hours. The constraint we observed cognitively and the constraint we observe metabolically are the same constraint viewed from different levels. And the clinical implications are immediate. Mitochondrial dysfunction appears early in Alzheimer's progression. Before widespread neuronal loss. Amyloid-β accumulates in mitochondrial membranes. Tau promotes excessive mitochondrial fission. The neurodegeneration connection is not peripheral. It is central. December 2024 discovery: boost mitochondrial transcriptional coupling in aged mice, and memory performance improves. The reframe is simple. The synapse is where we observe memory. The mitochondrion is where we power it. Synaptic targets have dominated drug discovery for cognitive disorders for decades. The results have been modest. Perhaps because we have been intervening downstream of the rate-limiting step. The next generation of cognitive therapeutics may target organelles, not receptors. #Neuroscience #DrugDiscovery #Mitochondria

🧠💡 New Insights into Alzheimer's Disease: The Critical Role of Mitochondrial Dysfunction 💡🧠 In a landmark study comparing isogenic wild-type with Alzheimer's disease (AD) mutant human induced pluripotent stem cell-derived cerebrocortical neurons, researchers have uncovered pivotal insights into the role of mitochondrial dysfunction in the cognitive decline associated with AD. The investigation has established a direct correlation between impaired mitochondrial metabolism and synaptic loss, the latter being a principal pathological hallmark of AD. Utilizing the Seahorse platform for a detailed examination of cellular energy mechanisms, the study highlighted significant disruptions in glycolysis and oxidative phosphorylation processes within these neurons. A notable obstruction was identified in the tricarboxylic acid (TCA) cycle, specifically at the 𝜶-ketoglutarate dehydrogenase (𝜶KGDH)/succinyl coenzyme-A synthetase juncture, crucial for the conversion of 𝜶-ketoglutarate to succinate. The research further illuminated an unusual pattern of S-nitrosylation on 𝜶KGDH subunits, leading to a consequential inhibition of their enzymatic activity. This irregular modification was observed not only in neurons derived from AD mutants but also in postmortem human AD brains, suggesting a potential universal marker for the disease's pathology. A glimmer of hope emerged from the application of dimethyl succinate, a cell-permeable TCA cycle substrate derivative, which showed a partial restoration of mitochondrial bioenergetic functionality and a significant reversal of synapse loss in the AD neuron models. This groundbreaking work suggests that targeting mitochondrial dysfunction could offer new therapeutic pathways for mitigating synaptic loss and cognitive deterioration in Alzheimer's disease, paving the way for novel interventions in the fight against this debilitating condition. link: https://lnkd.in/gY5wmT4r #AlzheimersResearch #MitochondrialDysfunction #Neuroscience #InnovativeTherapies #CognitiveDecline

TAU DOES NOT JUST “MISFOLD.” IT PRECIPITATES OUT OF A CHANGING WATER TERRAIN. Most discussions of Alzheimer’s disease stop at genetics, proteomics, or enzymes. But the deeper story — the story that sits underneath tau pathology — is a story of water, oxygen, and mitochondrial failure. Tau tangles do not appear out of nowhere. They emerge from a terrain shift that begins much earlier: when mitochondria become hypoxic, disordered, and unable to maintain the redox structure of intracellular water. Here is the piece medicine keeps missing: When mitochondria are deprived of oxygen, they cannot maintain the charge dynamics that keep intracellular water structured. Mitochondria normally generate an exquisitely ordered water matrix — hydrogen-bonded, slightly viscous, electrically coherent. This structure is what keeps thousands of proteins, including tau, suspended in a soluble, functional phase. But under hypoxia, that system collapses: • ATP production drops • the proton gradient disintegrates • electrons back up and leak • water loses coherence and becomes disordered • intracellular viscosity changes And when the water around a protein changes, the protein changes with it. Tau’s solubility is not a fixed property. It depends entirely on the hydration shell that surrounds it — a shell that mitochondria regulate from the inside out. When the mitochondrial water matrix destabilizes: • tau loses its soluble phase • chaperone systems (which require ATP) fail • tau proteins fall out of solution • and begin to polymerize into fibrils • which then twist into neurofibrillary tangles This is not random misfolding. It is a phase transition — driven by the breakdown of mitochondrial water structuring. A remarkable analogy exists in the natural world. In low-oxygen, redox-imbalanced environments, bacteria like Gallionella produce long, filamentous mineral aggregates as water structure collapses around them. They are not “broken”; they are responding to a changed terrain. Tau behaves the same way. It is responding to: • hypoxia • oxidative stress • metal imbalance • loss of manganese-dependent redox stability • and the collapse of mitochondrial coherence Alzheimer’s pathology is not simply genetic. It is biophysical. It is energetic. It is water-based. This reframing opens a new frontier: If we restore mitochondrial oxygenation, redox stability, hydration integrity, and micronutrient balance (including manganese), we may prevent the very terrain that forces tau into tangles. Neurodegeneration begins long before the plaques. It begins in the water. #Mitochondria #Neuroscience #AlzheimersDisease #Neurodegeneration #TauProtein #CellularTerrain #Hypoxia #WaterBiology #Manganese #BrainHealth

Neurodegenerative disease isn’t just a brain problem — it’s an energy problem. Across Alzheimer’s, Parkinson’s, ALS, and other neurodegenerative conditions, one pattern keeps showing up: Mitochondrial dysfunction Neurons are some of the most energy-dependent cells in the body. When mitochondria falter, everything downstream suffers: • Energy production drops • Oxidative stress rises • Cellular repair slows • Inflammation accelerates This isn’t a single-pathway issue. It’s a systems failure — metabolism, immunity, redox balance, and cellular communication all intersect at the mitochondria. What’s exciting is the shift in thinking: Instead of chasing symptoms late in the disease process, research is increasingly focused on protecting and restoring mitochondrial health early. That means: • Supporting energy production • Reducing oxidative stress • Improving mitochondrial quality control (repair + renewal) • Using compounds that act across multiple pathways, not just one target This is where longevity science, precision medicine, and neuroprotection converge. The future of brain health won’t be found in a single drug — It will be built through data-guided, system-level strategies that support cellular energy and resilience over time. This isn’t magic. It’s biology. And it’s where medicine is headed. #Mitochondria #Neurodegeneration #LongevityMedicine #SystemsBiology #BrainHealth #PrecisionHealth #FunctionalMedicine #Medicine4Point0 #HealthOptimization

As a medical school professor, I now believe the biggest mistake in Alzheimer's research was ignoring metabolism. A comprehensive Frontiers in Neurology review makes the case clear: mitochondrial dysfunction and metabolic failure happen YEARS before amyloid plaques or memory loss. The evidence is overwhelming: - Brain glucose utilization drops early, detectable on FDG-PET scans - Mitochondria fragment and produce less ATP - Oxidative stress surges before any protein aggregation - Insulin resistance in the brain disrupts neuronal energy supply This creates a vicious cycle: metabolic failure drives amyloid and tau pathology, which worsens metabolism further. As I discuss in "Lies I Taught in Medical School," we were taught to chase plaques. We should have been protecting metabolism. Full breakdown coming on the Health Longevity Secrets podcast. Source: https://lnkd.in/g_CWcMBF #MetabolicHealth #Alzheimers #BrainHealth #Longevity #HealthLongevitySecrets

This week's most significant findings centered on a groundbreaking achievement in neuroscience and medicine: research has definitively demonstrated for the first time that mitochondrial dysfunction directly contributes to memory loss in neurodegenerative diseases. Published in Nature Neuroscience (August 2025), the findings demonstrate that enhancing mitochondrial activity can reverse memory decline in experimental models, re-establishing energy metabolism as a core cause of cognitive impairment, previously viewed as a "downstream symptom." This breakthrough opens up entirely new avenues for the treatment of Alzheimer's disease, dementia, and other related conditions. The study repositions mitochondria as key regulators of memory and cognition, offering new avenues for future interventions: potentially halting or even reversing cognitive decline before irreversible damage occurs. A significant turning point in the field, this discovery not only deepens our understanding of the pathogenesis of neurodegenerative diseases but also offers new hope for millions of patients worldwide. #Neuroscience #NatureNeuroscience #Mitochondria #MemoryLoss #Neurodegeneration #Alzheimers #DementiaResearch #BiomedicalInnovation #HealthyAging #CognitiveHealth #LifeSciences #MedicalBreakthroughs #WeeklyScience #TranslationalResearch #CSTEAMBiotech #AASE

Parkinson’s Breakthrough: Scientists Identify Molecular Trigger of Neuron Damage Introduction Researchers at Case Western Reserve University School of Medicine have identified a critical molecular interaction that helps explain how toxic protein buildup in Parkinson’s disease leads to brain cell damage. The study connects two long-suspected contributors—alpha-synuclein and mitochondrial dysfunction—into a single, actionable mechanism. The Missing Link Alpha-synuclein toxicity Parkinson’s disease is marked by abnormal clumps of alpha-synuclein proteins that accumulate in neurons. Mitochondrial weakness The disease is also associated with impaired mitochondria, the cellular structures responsible for producing energy. New connection discovered The research shows that alpha-synuclein binds directly to an enzyme called ClpP, which regulates mitochondrial waste removal. Functional disruption This binding interferes with mitochondrial function, reducing energy production and contributing to the decline in dopamine-producing neurons. A Potential Therapeutic Strategy Decoy protein design Scientists engineered a short protein fragment called CS2 to act as a decoy. Protective mechanism CS2 diverts alpha-synuclein away from ClpP, preventing mitochondrial damage. Preclinical results In laboratory-grown neurons, human brain tissue samples, and mouse models, CS2 reduced inflammation and improved motor and cognitive function. Root-cause targeting Researchers emphasize that this strategy addresses a molecular driver of disease rather than merely alleviating symptoms. Timeline and Caution Clinical pathway Human trials are estimated to be at least five years away, pending safety and efficacy validation. Biological complexity Because mitochondrial pathways are fundamental to many cellular processes, unintended effects must be carefully studied. Why It Matters Parkinson’s is a multifactorial and progressive neurodegenerative disorder, making it difficult to isolate cause from consequence. By identifying a precise biochemical interaction that damages neurons and demonstrating a way to interrupt it, this research provides both mechanistic clarity and therapeutic direction. If validated in humans, mitochondria-targeted strategies like CS2 could redefine treatment—shifting from symptom management toward modifying disease progression itself.